Search

Paediatric guidance

British Society for Rheumatology paediatric guidance notes have been ratified by BSPAR section council. They are designed to support those working in paediatric and adolescent care.

Guidance notes are developed to support professionals in several ways, including encouraging a consistent approach to care delivery, promoting the effective use of resources and reducing the likelihood of inappropriate care. Overall, the paramount potential benefit is the improvement of the quality of care received by the patient and thus better health outcomes.

Treatment approaches can vary between clinicians and these guidance notes provide an opportunity to set out best practice based on current evidence or expert consensus. We hope that they will help to increase consistency in practice and thereby promote the highest standards of care.

Recommendations provided are intended to improve the quality of clinical decision-making, but each individual circumstance may be different and this should be taken into consideration. These notes are subject to periodic revision, and we welcome your feedback on any of the documents below.

Please note that many of these documents have been produced in collaboration with other organisations, details of which can be found within each specific guidance note.

Current guidance

Standards of care for JIA A statement of minimum standards of care required by children and young people with JIA

Find out more
Screening for Uveitis in JIA
Guidance for screening to reduce the incidence of visual impairment in children and young people with JIA

Find out more
Prescribing for children and young people
Standards and responsibilities for shared care protocol for immuno-modulating drugs

Find out more
Core competencies for Clinical Nurse Specialists and Advanced Nurse Practitioners
Administering disease modifying anti-rheumatic drugs (DMARDs) and biologic therapies to children and young people with rheumatological conditions

Find out more

RCN guidance

Administering subcutaneous methotrexate for inflammatory arthritis Evidence-based guidance for the safe and confident administration of subcutaneous methotrexate in a variety of primary and secondary care settings

Find out more
Adolescent transition care
Two part guidance for seamless transfer

Find out more

PRES and SHARE guidance

Antiphospholipid syndrome Fourteen evidence-based recommendations for the diagnosis and treatment of paediatric antiphospholipid syndrome (APS).

Find out more
Autoinflammatory diseases
Evidence-based recommendations for the management of the autoinflammatory diseases cryopyrin associated periodic syndromes (CAPS), tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS) and mevalonate kinase deficiency (MKD).

Find out more
Dermatomyositis
Evidence-based recommendations for the diagnosis and treatment of patients with juvenile dermatomyositis. In total, the document sets out 7 overarching principles, 33 recommendations on diagnosis and 19 on therapy.

Find out more
 Lupus Evidence-based recommendations to optimise and disseminate management regimens for children and young adults with rheumatic diseases such as childhood-onset systemic lupus erythematosus (cSLE).  Recommendations for cSLE include 11 on diagnosis, 9 on disease monitoring and 5 on general treatment.

Find out more
 Transitional care This is the first international set of recommendations and standards for transitional care of young people with juvenile-onset rheumatic diseases and aims to facilitate high-quality models of care for new and existing services.

Find out more